News Image

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Provided By GlobeNewswire

Last update: May 12, 2025

Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%

Read more at globenewswire.com

APOGEE THERAPEUTICS INC

NASDAQ:APGE (6/13/2025, 8:00:01 PM)

After market: 44 -0.48 (-1.08%)

44.48

+2.62 (+6.26%)



Find more stocks in the Stock Screener

Follow ChartMill for more